Analysts are assessing the investment potential of several healthcare and pharmaceutical companies, including Eli Lilly, IGC Pharma, and 60 Degrees Pharmaceuticals. They are providing insights and recommendations for investors considering these stocks.

Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has requested additional clinical data regarding its experimental obesity pill, potentially delaying its approval.

Eli Lilly (LLY) has received FDA approval for its new weight management pill, Foundayo, marking a significant development in the treatment of obesity.

Eli Lilly (LLY) has seen gains driven by the strong performance and growth of its GLP-1 franchises drugs.

Bank of America analysts anticipate a limited impact on Eli Lilly's franchise despite Novo's recent GLP-1 price update.

Eli Lilly (LLY) is reportedly expanding its pharmaceutical pipeline through a new agreement involving Clazakizumab, as reported by Reuters.

An article advises investors not to be concerned about the prospects of Eli Lilly (LLY) and Company's Foundayo treatment, implying positive outlooks for the drug.

Financial analyst Jim Cramer discussed Eli Lilly's (LLY) potential dominance in the weight loss market and how Novo Nordisk (NVO) might face increased competition from it.

Eli Lilly (LLY) has announced its intention to acquire Centessa Pharmaceuticals in a deal valued at $7.8 billion.

Morgan Stanley has reaffirmed its 'Overweight' rating on Eli Lilly (LLY), highlighting the substantial growth potential of the company's new platform. This positive outlook is based on anticipated future developments.

Multiple financial institutions have updated their price targets and ratings for various companies, reflecting new outlooks on their performance and market conditions.

Eli Lilly (LLY) has announced the expansion of its pharmaceutical pipeline, driven by positive trial data and a new licensing agreement.

Jim Cramer shares his insights on Eli Lilly (LLY) and the growing market for weight loss drugs.

Eli Lilly (LLY) has been identified as one of the eight best beginner stocks to buy, according to a recent market analysis.

Jim Cramer has offered his perspective on whether Eli Lilly (LLY) stands out as the best healthcare stock for investors to consider.

Eli Lilly is reportedly planning to invest $3 billion in China over the next ten years, as reported by Reuters, signaling a significant expansion in the region.

Barclays has begun its coverage of Eli Lilly (LLY), expressing a positive outlook due to the company's robust standing in the obesity treatment market.